Anebulo Pharmaceuticals (ANEB) Non Operating Income (2020 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Non Operating Income of $620513.0 for Q4 2025, up 395.93% year-over-year from $125121.0 in Q4 2024, and up 508.91% quarter-over-quarter from $101906.0 in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Non Operating Income (2020 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Non Operating Income for 6 consecutive years, with $620513.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non Operating Income rose 395.93% year-over-year to $620513.0; the TTM figure through Dec 2025 stood at $1.1 million (up 233.11% YoY), while the FY2025 annual figure was $738718.0, up 590.06% from the prior year.
- Non Operating Income climbed to $620513.0 in Q4 2025 per ANEB's latest filing, from $101906.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $620513.0 in Q4 2025 and bottomed at -$26.6 million in Q2 2021.
- Historically, Non Operating Income has averaged -$1.3 million across 5 years, with a median of $10709.0 in 2024.
- Annual changes were most pronounced in 2023 — Non Operating Income surged 29748.58% — and 2024, when it sank 706.21%.
- Anebulo Pharmaceuticals' Non Operating Income stood at $1529.0 in 2021, then slumped by 1004.51% to -$13830.0 in 2022, then soared by 411.57% to $43090.0 in 2023, then jumped by 190.37% to $125121.0 in 2024, then soared by 395.93% to $620513.0 in 2025.
- Business Quant data shows ANEB's Non Operating Income at $620513.0 in Q4 2025, $101906.0 in Q3 2025, and $186056.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | 620,513.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 620,513.00 |
| Sep 30, 2025 | 101,906.00 |
| Jun 30, 2025 | 186,056.00 |
| Mar 31, 2025 | 216,153.00 |
| Dec 31, 2024 | 125,121.00 |
| Sep 30, 2024 | 211,388.00 |
| Jun 30, 2024 | -9,602.00 |
| Mar 31, 2024 | 10,709.00 |
| Dec 31, 2023 | 43,090.00 |
| Sep 30, 2023 | 62,855.00 |
| Jun 30, 2023 | -1,191.00 |
| Mar 31, 2023 | 66,070.00 |
| Dec 31, 2022 | -13,830.00 |
| Sep 30, 2022 | -212.00 |
| Jun 30, 2022 | 2,742.00 |
| Mar 31, 2022 | 3,153.00 |
| Sep 30, 2021 | 1,529.00 |
| Jun 30, 2021 | -26.63 Mn |
| Mar 31, 2021 | -3,701.00 |
| Sep 30, 2020 | -4,033.00 |